Tracy T Batchelor

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint Principles of pharmacotherapy
    Tracy Batchelor
    Department of Neurology, Harvard Medical School and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital, Boston, MA, USA Electronic address
    Handb Clin Neurol 134:149-62. 2016
  2. pmc Antiangiogenic therapy for glioblastoma: current status and future prospects
    Tracy T Batchelor
    Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts
    Clin Cancer Res 20:5612-9. 2014
  3. pmc Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
    Tracy T Batchelor
    Stephen E and Catherine Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 28:2817-23. 2010
  4. pmc Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide
    Elizabeth R Gerstner
    Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
    J Neurooncol 103:325-32. 2011
  5. pmc Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
    Tracy T Batchelor
    Department of Neurology, Department of Radiation Oncology, Department of Radiology, and Department of Pathology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114
    Proc Natl Acad Sci U S A 110:19059-64. 2013
  6. pmc Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate
    Ovidiu C Andronesi
    Athinoula A Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
    Clin Cancer Res 22:1632-41. 2016
  7. pmc Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation
    Elizabeth R Gerstner
    Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Neurology 70:401-2. 2008
  8. pmc VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer
    Elizabeth R Gerstner
    Department of Neurology, Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Nat Rev Clin Oncol 6:229-36. 2009
  9. pmc Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice
    Walid S Kamoun
    Edwin L Steele Laboratory, Department of Radiation Oncology, Stephen E and Catherine Pappas Center for Neuro Oncology, and AA Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Oncol 27:2542-52. 2009
  10. pmc Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy
    Kyrre E Emblem
    1 Department of Radiology and Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA 2 The Intervention Centre, Oslo University Hospital, Oslo, Norway
    Nat Med 19:1178-83. 2013

Collaborators

Detail Information

Publications64

  1. doi request reprint Principles of pharmacotherapy
    Tracy Batchelor
    Department of Neurology, Harvard Medical School and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital, Boston, MA, USA Electronic address
    Handb Clin Neurol 134:149-62. 2016
    ..Various techniques used to assess drug distribution to the brain will be reviewed. ..
  2. pmc Antiangiogenic therapy for glioblastoma: current status and future prospects
    Tracy T Batchelor
    Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts
    Clin Cancer Res 20:5612-9. 2014
    ..Predictive markers may allow appropriate patient enrichment, combination with chemotherapy may ultimately prove successful in improving overall survival, and novel agents targeting multiple proangiogenic pathways may prove effective...
  3. pmc Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
    Tracy T Batchelor
    Stephen E and Catherine Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 28:2817-23. 2010
    ..Glioblastoma is an incurable solid tumor characterized by increased expression of vascular endothelial growth factor (VEGF). We performed a phase II study of cediranib in patients with recurrent glioblastoma...
  4. pmc Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide
    Elizabeth R Gerstner
    Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
    J Neurooncol 103:325-32. 2011
    ..Vatalanib was well tolerated and this study demonstrates the safety of oral small molecule inhibitors in newly diagnosed GBM patients. Blood biomarkers may be useful as pharmacodynamic markers of response to anti-angiogenic therapies...
  5. pmc Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
    Tracy T Batchelor
    Department of Neurology, Department of Radiation Oncology, Department of Radiology, and Department of Pathology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114
    Proc Natl Acad Sci U S A 110:19059-64. 2013
    ..nonresponders early in the course of this expensive and potentially toxic form of therapy, and these results may provide new insight into the selection of glioblastoma patients most likely to benefit from anti-VEGF treatments. ..
  6. pmc Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate
    Ovidiu C Andronesi
    Athinoula A Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
    Clin Cancer Res 22:1632-41. 2016
    ....
  7. pmc Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation
    Elizabeth R Gerstner
    Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Neurology 70:401-2. 2008
  8. pmc VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer
    Elizabeth R Gerstner
    Department of Neurology, Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Nat Rev Clin Oncol 6:229-36. 2009
    ..Anti-VEGF agents might also be useful in other cancer-related conditions that increase vascular permeability, such as malignant pleural effusions or ascites...
  9. pmc Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice
    Walid S Kamoun
    Edwin L Steele Laboratory, Department of Radiation Oncology, Stephen E and Catherine Pappas Center for Neuro Oncology, and AA Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Oncol 27:2542-52. 2009
    ..Our goal was to determine whether alleviation of edema by anti-VEGF agents alone could increase survival in mice...
  10. pmc Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy
    Kyrre E Emblem
    1 Department of Radiology and Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA 2 The Intervention Centre, Oslo University Hospital, Oslo, Norway
    Nat Med 19:1178-83. 2013
    ..Thus, VAI has the potential to identify patients who would benefit from therapies. ..
  11. pmc A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients
    A Gregory Sorensen
    A A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Res 69:5296-300. 2009
    ..54; P = 0.004) and progression-free survival (rho = 0.6; P = 0.001). The vascular normalization index described here should be validated in randomized clinical trials...
  12. pmc Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib
    Elizabeth R Gerstner
    Departments of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Neuro Oncol 12:466-72. 2010
    ..ADC maps can be used to suggest regions of infiltrative tumor cells with anti-VEGF therapy and should be validated in future studies...
  13. pmc High-dose methotrexate for elderly patients with primary CNS lymphoma
    Jay Jiguang Zhu
    Department of Neurology, Tufts New England Medical Center, Boston, MA, USA
    Neuro Oncol 11:211-5. 2009
    ..High-dose MTX should be considered as a feasible treatment option in elderly patients with PCNSL...
  14. pmc Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation
    Marco C Pinho
    Departments of Radiology, Neurology, and Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA Athinoula A Martinos Center for Biomedical Imaging, Charlestown, Massachusetts, USA The Intervention Centre, Oslo University Hospital, Oslo, Norway Center for Neuro Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Oncologist 19:75-81. 2014
    ....
  15. pmc The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma
    David J Sher
    Harvard Radiation Oncology Program, Boston, MA, USA
    J Neurooncol 88:43-50. 2008
    ..We sought to determine the relative contribution of concomitant temozolomide in patients treated by concurrent and adjuvant TMZ versus adjuvant TMZ alone in the setting of newly diagnosed GBM...
  16. pmc Angiogenesis as a therapeutic target in malignant gliomas
    Andrew S Chi
    Department of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Oncologist 14:621-36. 2009
    ..Although challenges remain with this approach, ongoing studies may improve upon the promising initial benefits already observed in GBM patients...
  17. pmc Prospective, high-throughput molecular profiling of human gliomas
    Andrew S Chi
    Department of Neurology, Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    J Neurooncol 110:89-98. 2012
    ....
  18. pmc Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma
    Tracy T Batchelor
    Tracy T Batchelor, Rakesh K Jain, and Gregory Sorensen, Massachusetts General Hospital, Boston, MA Paul Mulholland, University College London, London Rao Gattamaneni, the Christie Foundation Trust Hospital, Manchester, United Kingdom Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium L Burt Nabors, University of Alabama at Birmingham, Birmingham, AL Mario Campone, Centre Rene Gauducheau, Saint Herblain, France Antje Wick, University of Heidelberg, Heidelberg, Germany Warren Mason, Princess Margaret Hospital, Toronto, Ontario, Canada Tom Mikkelsen, Henry Ford Hospital, Detroit, MI Surasak Phuphanich, Cedars Sinai Medical Center, Los Angeles, CA Lynn S Ashby, Barrow Neurological Institute, Phoenix, AZ John DeGroot, MD Anderson Cancer Center, Houston, TX Lawrence Cher, Austin Health Cancer Services Mark Rosenthal, Royal Melbourne Hospital, Melbourne, 2-1 Hirosawa
    J Clin Oncol 31:3212-8. 2013
    ....
  19. pmc Anti-vascular endothelial growth factor therapy for malignant glioma
    Elizabeth R Gerstner
    Stephen E and Catherine Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA
    Curr Neurol Neurosci Rep 9:254-62. 2009
    ..However, because most patients eventually relapse, more work is needed to understand mechanisms of disease escape, including vascular co-option of native brain blood vessels...
  20. doi request reprint Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas
    Elizabeth R Gerstner
    Department of Neurology, Division of Neuro Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Curr Opin Neurol 21:728-35. 2008
    ..This review will summarize new neuroimaging techniques, particularly MRI and PET imaging, that can be used to assess brain tumor growth and angiogenesis...
  21. pmc Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma
    Christine Lu-Emerson
    all authors, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA
    J Clin Oncol 33:1197-213. 2015
    ..In this article, we discuss the lessons learned from the trials conducted to date and how we could potentially use recent advances in GBM biology and imaging to improve outcomes of patients with GBM who receive antiangiogenic therapy...
  22. doi request reprint Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
    Shota Tanaka
    Stephen E and Catherine Pappas Center for Neuro Oncology, Boston, MA 02114, USA
    Nat Rev Clin Oncol 10:14-26. 2013
    ..In addition, we emphasize current biomarkers relevant to the management of patients with glioblastoma...
  23. pmc Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients
    Kourosh Jafari-Khouzani
    Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts K J K, W B, B R R, O C A Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts F L, D P C Department of Neurosurgery, Charité Medical University, Berlin, Germany F L High Field MR Center, Department of Biomedical Imaging and Image Guided Therapy, Medical University Vienna, Vienna, Austria W B Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts O R, G R G Pappas Center of Neuro Oncology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts E G, A S C, T T B Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts J U, H A S
    Neuro Oncol 18:1569-1578. 2016
    ..Here, we investigated the relationship between 2HG and FLAIR in mutant IDH glioma patients to determine whether 2HG mapping is valuable for radiotherapy planning...
  24. pmc Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study
    Milan G Chheda
    Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital, Yawkey 9 East, 55 Fruit Street, Boston, MA, 02114, USA
    J Neurooncol 121:627-34. 2015
    ..5 %; 95 % CI (1, 33 %)] and PFS6 was 15.8 % [95 % CI (3.9, 34.9 %)]. Vandetanib and sirolimus can be safely co-administered on a continuous, daily dosing schedule...
  25. pmc Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma
    Eudocia Q Lee
    Dana Farber Brigham and Women s Cancer Center, Harvard Medical School, Boston, Massachusetts E Q L, D A R, A D N, L N, R B, M L R, K H, C M, K H S, S C G, B W, K L L, P Y W University of Virginia, Charlottesville, Virginia D S University of Pittsburgh, Pittsburgh, Pennsylvania J D Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts A S C, T, T B, A M Central DuPage Hospital, Warrenville, Illinois S A G Northwestern University, Chicago, Illinois J J R
    Neuro Oncol 17:862-7. 2015
    ..We conducted a multicenter phase II trial of panobinostat combined with bevacizumab in patients with recurrent high-grade glioma (HGG)...
  26. pmc A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients
    Eudocia Q Lee
    Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts Harvard Medical School, Boston, Massachusetts
    Clin Cancer Res 21:3610-8. 2015
    ..We conducted a randomized, noncomparative, phase II study of radiation (RT) and temozolomide with or without vandetanib in patients with newly diagnosed glioblastoma (GBM)...
  27. pmc Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma
    Christine Lu-Emerson
    Department of Neurology, Radiation Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA
    Neuro Oncol 15:1079-87. 2013
    ..These data suggest that tumor-associated macrophages may participate in escape from antiangiogenic therapy and may represent a potential biomarker of resistance and a potential therapeutic target in recurrent glioblastoma. ..
  28. ncbi request reprint Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma
    Paul L Nguyen
    Massachusetts General Hospital, Department of Radiation Oncology, 100 Blossom St, Boston, MA 02114, USA
    J Clin Oncol 23:1507-13. 2005
    ..This study evaluates the efficacy and toxicity of whole-brain radiation therapy (WBRT) as salvage therapy for immunocompetent patients who failed initial high-dose methotrexate for primary CNS lymphoma (PCNSL)...
  29. ncbi request reprint Antiangiogenic agents for the treatment of glioblastoma
    Elizabeth R Gerstner
    1Massachusetts General Hospital Cancer Center and Harvard Medical School, Department of Neurology, Boston, Massachusetts, USA
    Expert Opin Investig Drugs 16:1895-908. 2007
    ..It seems likely that a combination of antiangiogenesis agents with other cytotoxic therapies will be required to achieve maximal efficacy...
  30. pmc Response criteria for glioma
    A Gregory Sorensen
    Harvard Medical School, Boston, MA, USA
    Nat Clin Pract Oncol 5:634-44. 2008
    ....
  31. pmc Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients
    Scott R Plotkin
    Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02114, U S A
    Otol Neurotol 31:1135-43. 2010
    ..We sought to determine the activity of erlotinib for progressive vestibular schwannoma (VS) associated with neurofibromatosis 2 (NF2)...
  32. pmc Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma
    Kensuke Tateishi
    Department of Neurosurgery, Translational Neuro Oncology Laboratory, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts
    Clin Cancer Res 22:4452-65. 2016
    ..We investigated whether targeting the Myc-driven metabolic state could be a selectively toxic therapeutic strategy for glioblastoma...
  33. doi request reprint A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme
    Jan Drappatz
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 73:222-7. 2009
    ....
  34. pmc Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma
    Jörg Dietrich
    Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Expert Opin Investig Drugs 18:1549-57. 2009
    ..Treatment strategies targeting angiogenesis have revealed promising results in preclinical studies and early clinical trials in patients with glioblastomas...
  35. pmc Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate
    Ovidiu C Andronesi
    Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Invest 123:3659-63. 2013
    ..Here, we review recent efforts to translate methodology using MRS to reliably measure in vivo D-2HG into clinical research. ..
  36. doi request reprint Primary central nervous system lymphoma
    Elizabeth R Gerstner
    Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA
    Arch Neurol 67:291-7. 2010
    ..Unfortunately, although durable remissions may be achieved for some patients with PCNSL, the tumor relapses in most cases. In this review, we will focus on PCNSL in the immunocompetent host...
  37. pmc Recent advances in treatment of primary central nervous system lymphoma
    Lakshmi Nayak
    Dana Farber Cancer Institute, Center for Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA
    Curr Treat Options Oncol 14:539-52. 2013
    ..There also is emphasis on quality of life parameters and neurocognitive status. Future treatment options should optimize high-efficacy rates while minimizing the risk of neurotoxicity...
  38. doi request reprint Imaging and response criteria in gliomas
    Elizabeth R Gerstner
    Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Curr Opin Oncol 22:598-603. 2010
    ..These new techniques are increasingly being incorporated into clinical trials and even into clinical practice. Therefore, it is important to be familiar with the available imaging techniques and their potential uses versus limitations...
  39. doi request reprint Vascular endothelial growth factor inhibitors in malignant gliomas
    Priscilla K Brastianos
    Stephen E and Catherine Pappas Center for Neuro Oncology, Department of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Target Oncol 5:167-74. 2010
    ..Unfortunately, antiangiogenic treatment inevitably fails in most patients. Further studies are needed to understand the molecular pathways that enable a tumor to evade antiangiogenic therapy...
  40. pmc Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion
    Kensuke Tateishi
    Department of Neurosurgery, Translational Neuro Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Cancer Cell 28:773-84. 2015
    ..NAD+ depletion activated the intracellular energy sensor AMPK, triggered autophagy, and resulted in cytotoxicity. Thus, we identify NAD+ depletion as a metabolic susceptibility of IDH1 mutant cancers. ..
  41. pmc Antiangiogenic therapy for glioblastoma
    Elizabeth R Gerstner
    Department of Neurology, Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Cancer J 18:45-50. 2012
    ..Unfortunately, the response to anti-VEGF therapy is transient, and the majority of patients eventually relapsed, so more work is needed to understand the mechanisms of tumor escape...
  42. pmc Standard chemoradiation for glioblastoma results in progressive brain volume loss
    Morgan J Prust
    From Harvard Medical School M J P, J D, Boston and Athinoula A Martinos Center for Biomedical Imaging, Department of Radiology M J P, K J K, J K C, P P, E R G, and Department of Neurology, Center for Neuro Oncology T T B, E R G, J D, Massachusetts General Hospital, Harvard Medical School, Boston, MA
    Neurology 85:683-91. 2015
    ..To investigate the effects of chemotherapy and cranial irradiation on normal brain tissue using in vivo neuroimaging in patients with glioblastoma...
  43. pmc A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma
    Elizabeth R Gerstner
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts E R G, D G D, R K J, T T B Johns Hopkins Medical Center, Baltimore, Maryland X Y, S G Martinos Center for Biomedical Imaging, Charlestown, Massachusetts E R G, M A L Henry Ford Hospital, Detroit, Michigan T M Memorial Sloan Kettering Cancer Center, New York, New York T J K Emory University, Atlanta, Georgia J J O University of Alabama, Birmingham, Alabama B L N Case Comprehensive Cancer Center, Cleveland, Ohio M S A Dana Farber Cancer Institute, Boston, Massachusetts P Y W
    Neuro Oncol 17:1386-92. 2015
    ..We designed a study of cediranib, a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor, combined with cilengitide, an integrin inhibitor...
  44. ncbi request reprint Treatment of relapsed central nervous system lymphoma with high-dose methotrexate
    Scott R Plotkin
    Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 10:5643-6. 2004
    ..The optimal management of these patients has not been determined. We performed a multicenter, retrospective study of high-dose methotrexate in patients with relapsed central nervous system lymphoma...
  45. pmc Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma
    Tracy T Batchelor
    Departments of Neurology T T B, E R G and Radiation Oncology T T B, D G D, Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts T T B, E R G, J G S Johns Hopkins University School of Medicine, Baltimore, Maryland X Y, S D, S G Cleveland Clinic, Cleveland, Ohio D P Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, North Carolina G J L Moffitt Cancer Center, Tampa, Florida S C Dana Farber Cancer Institute, Boston, Massachusetts P Y W
    Neuro Oncol . 2016
    ..Platelet-derived growth factor (PDGF) signaling is important in gliomagenesis and PDGF receptor-β is expressed on most endothelial cells in glioblastoma specimens...
  46. pmc Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma
    Jennie W Taylor
    Stephen E and Catherine Pappas Center for Neuro Oncology, Division of Hematology Oncology, Department of Neurology, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Yawkey 9E, Boston, MA, 02114, USA
    J Neurooncol 121:557-63. 2015
    ..Bosutinib monotherapy does not appear to be effective in recurrent glioblastoma. However, Src remains a potential target based on its upregulation in tumor samples and role in glioma invasion...
  47. pmc Insights into the biology of primary central nervous system lymphoma
    Maciej M Mrugala
    Stephen E and Catherine Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Curr Oncol Rep 11:73-80. 2009
    ..This review discusses recent advances in PCNSL biology, including immunologic and genetic risk factors, and focuses on the molecular alterations important in central nervous system lymphomagenesis...
  48. pmc Genome-wide comparison of paired fresh frozen and formalin-fixed paraffin-embedded gliomas by custom BAC and oligonucleotide array comparative genomic hybridization: facilitating analysis of archival gliomas
    Gayatry Mohapatra
    Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Acta Neuropathol 121:529-43. 2011
    ..In combination, these advances should facilitate genome-wide analysis of rare, small and/or histologically heterogeneous gliomas from FFPE tissues...
  49. pmc CNS Hodgkin lymphoma
    Elizabeth R Gerstner
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Blood 112:1658-61. 2008
    ....
  50. doi request reprint Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas
    Lakshmi Nayak
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 450 Brookline Avenue, Boston, MA, 02215, USA
    J Neurooncol . 2017
    ..This study met its primary endpoint and the MTD of aflibercept with radiation and concomitant and adjuvant temozolomide is 4 mg/kg every 2 weeks...
  51. pmc VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects
    Dan G Duda
    Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, COX 734, Boston, MA 02114, USA
    Trends Mol Med 13:223-30. 2007
    ....
  52. ncbi request reprint VEGF inhibitors in brain tumors
    Priscilla K Brastianos
    Department of Medical Oncology, Dana Farber Brigham and Women s Cancer Center, Massachusetts General Hospital, Boston, 02114, USA
    Clin Adv Hematol Oncol 7:753-60, 768. 2009
    ..Unfortunately, treatment inevitably fails. Further studies are needed to understand mechanisms of tumor resistance and to identify other therapeutic targets that mediate angiogenesis...
  53. pmc Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
    Priscilla K Brastianos
    Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts Broad Institute, Boston, Massachusetts
    Cancer Discov 5:1164-77. 2015
    ..Genomic analysis of brain metastases provides an opportunity to identify potentially clinically informative alterations not detected in clinically sampled primary tumors, regional lymph nodes, or extracranial metastases...
  54. doi request reprint Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline
    Brian V Nahed
    Department of Neurosurgery, Massachusetts General Hospital, 15 Parkman Street, Wang 745, Boston, MA, 02114, USA
    J Neurooncol 125:609-30. 2015
    ..These recommendations apply to adult patients with recurrent low-grade glioma (LGG) with initial pathologic diagnosis of a WHO grade II infiltrative glioma (oligodendroglioma, astrocytoma, or oligo-astrocytoma)...
  55. pmc AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
    Tracy T Batchelor
    Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Cancer Cell 11:83-95. 2007
    ..Our study provides insight into different mechanisms of action of this class of drugs in recurrent glioblastoma patients and suggests that the timing of combination therapy may be critical for optimizing activity against this tumor...
  56. doi request reprint Glioblastoma care in the elderly
    Justin T Jordan
    Pappas Center for Neuro Oncology, Massachusetts General Hospital, Boston, Massachusetts
    Cancer 122:189-97. 2016
    ..MGMT promoter methylation status has specifically demonstrated utility in predicting the efficacy of temozolomide and should be considered in treatment decisions when possible. Cancer 2016;122:189-197. © 2015 American Cancer Society. ..
  57. doi request reprint Primary central nervous system lymphoma: overview of current treatment strategies
    Priscilla K Brastianos
    Stephen E and Catherine Pappas Center for Neuro Oncology, Division of Hematology and Oncology, Department of Neurology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    Hematol Oncol Clin North Am 26:897-916. 2012
    ..The standard treatment is a methotrexate-containing chemotherapy regimen. The timing and dose of whole-brain radiation therapy is controversial, given the significant risks of late neurotoxic effects, particularly in elderly patients...
  58. pmc Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma
    William T Curry
    Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts Cancer Center, Massachusetts General Hospital, Boston, Massachusetts Harvard Medical School, Boston, Massachusetts
    Clin Cancer Res 22:2885-96. 2016
    ..We examined the feasibility and safety of vaccination with irradiated autologous glioma cells mixed with irradiated GM-K562 cells in patients undergoing craniotomy for recurrent malignant glioma...
  59. pmc BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications
    Dora Dias-Santagata
    Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 6:e17948. 2011
    ..1%) giant cell GBM (gcGBM). The finding that BRAF V600E mutations are common in the majority of PXA has important therapeutic implications and may help in differentiating less aggressive PXAs from lethal gcGBMs and GBMs...
  60. ncbi request reprint Primary central nervous system lymphoma: presentation, diagnosis and staging
    April F Eichler
    Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Neurosurg Focus 21:E15. 2006
    ..Testicular ultrasonography studies should be considered in men. In patients who cannot undergo LP or in those with evidence of spinal cord dysfunction, contrast-enhanced MR imaging of the entire spine should be considered...
  61. doi request reprint Current Management Concepts: Primary Central Nervous System Lymphoma, Natural Killer T-Cell Lymphoma Nasal Type, and Post-transplant Lymphoproliferative Disorder
    Tracy T Batchelor
    From the Division of Hematology Oncology, Departments of Neurology and Radiation Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA Department of Medical Oncology, National Cancer Centre, Duke National University of Singapore Medical School, Singapore Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
    Am Soc Clin Oncol Educ Book 35:e354-66. 2016
    ..These diseases require a multidisciplinary complex team approach. This article will update current management approaches and concepts. ..
  62. pmc Computationally simple analysis of matched, outcome-based studies of ordinal disease states
    Rebecca A Betensky
    Department of Biostatistics, Harvard School of Public Health, Boston, MA, U S A
    Stat Med 34:2514-27. 2015
    ..We apply our methods to the Massachusetts General Hospital glioblastoma study...
  63. pmc Sporadic hemangioblastomas are characterized by cryptic VHL inactivation
    Ganesh M Shankar
    Departments of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA
    Acta Neuropathol Commun 2:167. 2014
    ..Our findings support the central role of VHL inactivation in the molecular pathogenesis of both familial and sporadic hemangioblastomas...
  64. pmc Brain tumor cells in circulation are enriched for mesenchymal gene expression
    James P Sullivan
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts Department of Medicine, Harvard Medical School, Boston, Massachusetts
    Cancer Discov 4:1299-309. 2014
    ..Thus, a mesenchymal subset of GBM cells invades the vasculature and may proliferate outside the brain...